Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Researchers evaluated the data of 50 specimens from patients who underwent TURBT and cystectomy for UC.
Dr. Prasad provides updates on the positive DOR data observed with UGN-102 for LG-IR-NMIBC in the ENVISION trial.
UroGen began the process of a rolling New Drug Application to the FDA for mitomycin as a treatment for patients with NMIBC.
Dr. Li describes his post hoc analysis and findings regarding patients with BCG–unresponsive, high-risk NMIBC in ...
Dr. Li details the final results of CORE-001, a phase-2, single arm study of cretostimogene combined with pembrolizumab.
Urinary tumor DNA predicts residual bladder cancer pre-surgery, improving assessments and treatment, ASCO 2024 study finds
The CORE-001 trial began in 2020 to study the breakthrough therapy cretostimogene with pembrolizumab for high-risk NMIBC.
Dr. Li rationalizes the design and potential impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Dr. Li provides commentary on the rationale, design, and impact of the MoonRISe-1 study for intermediate-risk NMIBC.
The primary end point of the analysis of cohort B was 12-month disease-free survival.
Dr. Soon-Shiong provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept for NMIBC.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Intravesical EMDA/MMC can serve as a safe and effective option for patients with high-risk NMIBC who fail BCG therapy.
A phase 2 clinical trial assessed combination intravesical gemcitabine and docetaxel for BCG-naïve NMIBC.
uMRD profiling determines mutations connected with urothelial carcinoma through next-generation sequencing.
Patients received weekly doses of docetaxel 80 mg, gemcitabine 1000 mg or 2000 mg, and biweekly cisplatin 100 mg.
The FDA approved Anktiva for patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.